Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Rational cancer therapy

Nature Medicine volume 1, pages 747–748 (1995)Cite this article

As our knowledge of the basis of different cancers grows, so does the arsenal of specific weapons with which to fight the disease (pages 792–797).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bishop, J.M. Molecular themes in oncogenesis. Cell 64, 235–248 (1991).

    Article  CAS  Google Scholar 

  2. Kohl, N.E. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1, 792–797 (1995).

    Article  CAS  Google Scholar 

  3. Lowy, D.R. & Willumsen, B.M. Function and regulation of Ras. Annu. Rev. Biochem. 62, 851–891 (1993).

    Article  CAS  Google Scholar 

  4. Bos, J.L. ras oncogenes in human cancer: A review. Cancer Res. 49, 4682–4689 (1989).

    CAS  PubMed  Google Scholar 

  5. Stacey, D.W., DeGudicibus, S.R. & Smith, M.R., ras activity and tumor cell proliferation. Exp. cell Res. 171, 232–242 (1987).

    Article  CAS  Google Scholar 

  6. Gibbs, J.B., Oliff, A. & Kohl, N.E. Farnesyltransferase inhibitors - Ras research yields a potential cancer therapeutic. Cell 77, 175–178 (1994).

    Article  CAS  Google Scholar 

  7. Reiss, Y., Goldstein, J.L., Seabra, M.C., Casey, P.J. & Brown, M.S. Inhibition of purified p21 ras famesyl-protein transferase by Cys-AAX tetrapeptides. Cell 62, 81–88 (1990).

    Article  CAS  Google Scholar 

  8. Kohl, N.E. et al. Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science 260, 1934–1937 (1993).

    Article  CAS  Google Scholar 

  9. James, G.L. et al. Benzodiazepine peptidomimetics — potent inhibitors of ras farnesylation in animal cells. Science 260, 1937–1942 (1993).

    Article  CAS  Google Scholar 

  10. Manne, V. et al. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene 10, 1763–1779 (1995).

    CAS  PubMed  Google Scholar 

  11. Kohl, N.E. et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. natn. Acad. Sci. U.S.A. 91, 9141–9145 (1994).

    Article  CAS  Google Scholar 

  12. Cox, A.D. et al. The CAAX peptidomimetic compound b581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. biol. Chem. 269, 19203–19206 (1994).

    CAS  PubMed  Google Scholar 

  13. Jordan, V.C. The role of tamoxifen in the treatment and prevention of breast cancer. Curr. Prob. Cancer 16, 129–176 (1992).

    CAS  Google Scholar 

  14. Dexter, D.D., Diamond, M., Crevling, J. & Chen, S.-F. Chemotherapy of mammary carcinomas arising in transgenic mice. Invest. New Drugs 11, 161–168 (1993).

    Article  CAS  Google Scholar 

  15. Prendergast, G.C. et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Molec. cell. Biol. 14, 4193–4202 (1994).

    Article  CAS  Google Scholar 

  16. James, G.L., Goldstein, J.L. & Brown, M.S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. biol Chem. 270, 6221–6226 (1995).

    Article  CAS  Google Scholar 

  17. James, G.L., Brown, M.S., Cobb, M.H. & Goldstein, J.L. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed rat-1 cells, but not in untransformed cells. J. biol Chem. 269, 27705–27714 (1994).

    CAS  PubMed  Google Scholar 

  18. Mulcahy, L.S., Smith, M.R. & Stacey, D.W. Requirements for ras proto-oncogene function during serum stimulated growth of NIH 3T3 cells. Nature 313, 241–243 (1985).

    Article  CAS  Google Scholar 

  19. Papageorge, A.G. et al. A transforming ras gene can provide an essential function ordinarily supplied by an endogenous ras gene. Molec. cell Biol 6, 1843–1846 (1986).

    Article  CAS  Google Scholar 

  20. Stacey, D.W., Feig, L.A. & Gibbs, J.B. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Molec. cell. Biol. 11, 4053–4064 (1991).

    Article  CAS  Google Scholar 

  21. Vaziri, C. & Faller, D.V. Repression of platelet-derived growth factor beta-receptor expression by mitogenic growth factors and transforming oncogenes in murine 3T3 fibroblasts. Molec. cell. Biol. 15, 1244–1253 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, 20892, USA

    Douglas R. Lowy

  2. Department of Molecular Cell Biology, University of Copenhagen, DK-1353, Copenhagen, Denmark

    Berthe M. Willumsen

Authors
  1. Douglas R. Lowy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Berthe M. Willumsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lowy, D., Willumsen, B. Rational cancer therapy. Nat Med 1, 747–748 (1995). https://doi.org/10.1038/nm0895-747

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0895-747

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing